IL6 and metastatic malignant neoplasm: In conclusion, we have validated two prognostic scores (score A: PS plus LDH level, and score B: PS plus lymphocyte count) and confirmed that combination of PS and biological covariates such as serum albumin concentration, LDH level, lymphocyte count, thrombocytopenia and IL-6 level is an effective strategy to predict survival for patients with advanced or metastatic cancer receiving further treatment after first-line failure.